Information  X 
Enter a valid email address

Indivior PLC (INDV)

  Print      Mail a friend

Tuesday 01 October, 2019

Indivior PLC

Notice of Results

RNS Number : 0385O
Indivior PLC
01 October 2019
 

 

Indivior to Announce 2019 Year-to-Date and Third Quarter Results October 31st

Slough, UK, and Richmond, VA - 1 October 2019 - Indivior PLC (LON: INDV) today announced that it will release its 2019 year-to-date and third quarter results on Thursday, October 31st at 11:00 London time (7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exchange Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.indivior.com.

Key members of Indivior's leadership team led by Shaun Thaxter, Chief Executive Officer, will host a conference call to discuss the results and address questions from qualified analysts and investors at 12:00 London time (8:00 a.m. U.S. Eastern) on October 31st.

Access the Live Results Webcast October 31st

The webcast event will be available on the "Investors" section of the company's website at www.indivior.com. The webcast link is https://edge.media-server.com/mmc/p/tcgvargq. Participants also may access the results presentation telephonically: US participants +1-631-510-7495; international participants +44(0)2071-928000. Please reference confirmation number 7297368. A replay of the presentation will be available at www.indivior.com.

About Indivior

Indivior is a global specialty pharmaceutical company with a 20-year legacy of leadership in patient advocacy and health policy while providing education on evidence-based treatment models that have revolutionized modern addiction treatment. Our vision is for all patients around the world to have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. The name is the fusion of the words individual and endeavor, and the tagline "Focus on you" makes the Company's commitment clear. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of opioid dependence treatments, Indivior has a strong pipeline of product candidates designed to both expand on its heritage in this category and address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder and schizophrenia. Headquartered in the United States in Richmond, VA, Indivior employs more than 800 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

Media Contacts:

US
[email protected]
+1 804-594-0836

UK
Tulchan Communications
+44 207-353-4200

Investor Contact:

Jason Thompson, Indivior
Vice President, Investor Relations
+1 804-402-7123
[email protected]

 

-ends-


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOREANNXAEDNEFF

a d v e r t i s e m e n t